Fierce Biotech2d
Unity's eye treatment fails to match Eylea, though analysts still see a path forward
Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...
Endpoints News2d
Two biotechs fail to beat or match Re­gen­eron's Eylea in key tri­als
Opthea's sozinibercept and Unity's UBX1325 fail to match Regeneron's Eylea in separate eye disease trials; Opthea faces ...
Opthea Phase 3 Trial Fails To Meet Primary Endpoint, Faces Financial Uncertainty
Opthea's Phase 3 COAST trial for wet AMD did not meet its primary endpoint, raising financial concerns as the company faces ...
Ophthalmology Times7d
Aflibercept treat-and-extend regimen for neovascular AMD: 5-year outcomes
The investigators retrospectively evaluated 126 consecutive treatment-naïve nAMD patients (126 eyes) who received a loading ...
Zacks Investment Research on MSN1d
UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study
Shares of UNITY Biotechnology UBX crashed 28.8% yesterday, following mixed results from a mid-stage non-inferiority study of ...
Business Insider1mon
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing AVT29, a biosimilar candidate for Eylea ® HD (aflibercept) 8 mg.
pharmaphorum4d
4DMT gene therapy cuts need for Eylea in wet AMD trial
They all had severe disease and a high treatment burden with an average of 10 injections with Eylea (aflibercept), a widely-used VEGF inhibitor sold by Bayer and Regeneron, in the last 12 months.
Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?
Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...